- Home
- NEXN vs BCYC Comparison
NEXN vs BCYC Comparison
Compare NEXN & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEXN | BCYC |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.2M | 438.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NEXN | BCYC |
|---|---|---|
| Price | $6.46 | $7.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $12.13 | ★ $18.73 |
| AVG Volume (30 Days) | ★ 434.2K | 320.6K |
| Earning Date | 11-13-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 237.45 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $376,353,000.00 | $28,339,000.00 |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | ★ 7.80 | N/A |
| 52 Week Low | $6.08 | $6.03 |
| 52 Week High | $12.60 | $21.50 |
Technical Indicators
Market Signals| Indicator | NEXN | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 50.66 |
| Support Level | $6.35 | $6.76 |
| Resistance Level | $6.71 | $7.83 |
| Average True Range (ATR) | 0.26 | 0.42 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 29.70 | 58.06 |
Price Performance
Historical ComparisonAbout NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.